Pancreatic cancer is one of the most aggressive and challenging malignancies. Most patients develop exocrine tumors and, less commonly, pancreatic neuroendocrine tumors (PanNETs). Exocrine tumors can be further categorized as pancreatic ductal adenocarcinoma (PDAC), acinar cell carcinoma, and intraductal papillary mucinous neoplasms (IPMNs). Techniques including Western blots, ELISA, flow cytometry, co-immunoprecipitation, and immunohistochemistry can distinguish among the different types of pancreatic cancer and provide vital information about cell proliferation and disease progression, which is critical for the early detection, prognosis/monitoring, and treatment of the disease.
NeoBiotechnologies proudly offers a comprehensive selection of antibodies for ovarian cancer research (see the table below), with a particular emphasis on IHC-validated antibodies targeting pancreatic cancer protein markers. Our antibodies are rigorously validated for specificity, ensuring precise and reliable results.